The AstraZeneca stock price has seen significant volatility with shares occasionally drpping yet still outperforming the market overall. Year-to-date the stock rose 18%, leading to mixed reviews on whether investors should buy. Moves such as Banco Santander's selling of over 11k shares of AstraZeneca and it being upgraded from 'Hold' to 'Buy' ahead of Q2 2024 earnings have contributed to market sentiments. The company's growth target for 2024 lends further optimism, but its ambitious plans to yield $80 billion by 2030 left investors divided.
While being recognised as a top momentum stock for long-term growth, quarterly performance had a mix of highs and lows. A surge following better-than-expected profits, and demand for its cancer drugs, was counterbalanced by reports of stock trading lower and weak quarterly reports.
Its decision to withdraw the Covid-19 vaccine from the European market caused a spike in stocks whereas a disappointing advanced lung cancer trial led to a slump. Other highlights included the company's improved performance in the European sustainability market and growth fuelled by next-gen cancer therapies.
AstraZeneca Stocks News Analytics from Wed, 18 Oct 2023 07:00:00 GMT to Sun, 21 Jul 2024 17:48:19 GMT - Rating 5 - Innovation 0 - Information 7 - Rumor -3
